ADCT (ADC Therapeutics) Institutional Ownership: 67.09% (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADCT ADC Therapeutics SA ADCT
41 GF Score
Price $1.26
GF Value $2.09
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is ADC Therapeutics Institutional Ownership?

ADC Therapeutics ADCT -6.67% 41 Institutional Ownership is 67.09% as of Jul. 21, 2026. GuruFocus rates ADCT with a GF Score™ of 41/100 and a GF Value™ of $2.09 (Possible Value Trap). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ADC Therapeutics's institutional ownership is 67.09%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ADC Therapeutics's Insider Ownership is 3.79%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ADC Therapeutics's Float Percentage Of Total Shares Outstanding is 84.74%.

ADC Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for ADC Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADC Therapeutics Institutional Ownership Chart

ADC Therapeutics Historical Data

The historical data trend for ADC Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 9.19 8.38 8.52 12.72 12.59 12.76 15.98 15.94 16.05 16.85
ADCT
41GF Score
ADC Therapeutics SA ADCT
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADC Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 67.09% mean?
ADC Therapeutics (ADCT) has a Institutional Ownership of 67.09% as of Jul. 21, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on ADC Therapeutics and its competitors.
Is ADC Therapeutics' Institutional Ownership too high?
ADC Therapeutics' current Institutional Ownership is 67.09%. Overall, ADC Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ADC Therapeutics' Institutional Ownership compare to GNLX and VXRT?
ADC Therapeutics' Institutional Ownership of 67.09% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on ADC Therapeutics and its competitors. ADC Therapeutics's current Institutional Ownership is 67.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, ADC Therapeutics (ADCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.09, compared to a current price of $1.26 — trading 39.7% below its estimated fair value. The current Institutional Ownership is 67.09%. ADC Therapeutics' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For ADC Therapeutics (ADCT), the current Institutional Ownership is 67.09% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADC Therapeutics (ADCT) Overvalued in 2026?

Based on GuruFocus' analysis, ADC Therapeutics stock appears to be undervalued. The current stock price of $1.26 is trading 39.7% below its estimated GF Value™ of $2.09. GuruFocus considers ADC Therapeutics to be Possible Value Trap.

Key valuation signals for ADCT:

  • Institutional Ownership: 67.09%
  • GF Value™: $2.09 vs. price of $1.26 (39.7% below fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the ADCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADC Therapeutics Business Description

Address Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
41GF Score

Get the complete analysis for ADCT

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.26
Price
$2.09
GF Value